Sun Pharma Advanced Research Company (SPARC) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
9 Feb, 2026Executive summary
Board approved unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025.
Financial statements reviewed by independent auditors with no material misstatements identified.
Financial highlights
Q3 consolidated revenue from operations: ₹845 lakhs, down from ₹1,491 lakhs in Q3 FY24.
Q3 consolidated net loss: ₹8,042 lakhs, compared to ₹7,951 lakhs loss in Q3 FY24.
Nine-month consolidated net loss: ₹20,814 lakhs, compared to ₹28,274 lakhs loss in the prior year period.
Basic and diluted loss per share for Q3: ₹2.48, compared to ₹2.45 in Q3 FY24.
Outlook and guidance
Company and group continue as a going concern, supported by a promoter group entity.
Monitoring ongoing regulatory changes and their financial impact.
Latest events from Sun Pharma Advanced Research Company
- Q1 FY27 saw normalized revenue and a net loss following a major one-time PRV sale in Q4.SPARC
Q1 26/27 - Exceptional PRV income drove a major profit rebound and strengthened equity in FY26.SPARCQ4 25/26
- Lead programs SCD153 and MUC1 ADC/SBO-154 advance, driven by partnerships and cost savings.SPARCR&D Day 2026
- Losses narrowed but remain significant; promoter support continues to underpin operations.SPARCQ2 25/26
- Net loss narrowed in Q1 FY26 as revenue declined and R&D focus continued.SPARCQ1 25/26
- Prioritizing oncology and immunology assets, pursuing cash catalysts and clinical milestones.SPARCStatus Update
- Net loss deepened in Q2 FY25 amid falling revenues and persistent high expenses.SPARCQ2 24/25
- Net loss persists amid declining revenue, with operations supported by promoter group backing.SPARCQ1 24/25
- SPARC narrowed its annual loss and plans to raise up to Rs. 1,800 crores for future growth.SPARCQ4 24/25